• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

人类 II 型拓扑异构酶中的自然突变序列多样性。

Naturally mutagenic sequence diversity in a human type II topoisomerase.

机构信息

Department of Biophysics and Biophysical Chemistry, Johns Hopkins University School of Medicine, Baltimore, MD 21205.

Pharmaceutical Sciences Department, University of Illinois College of Pharmacy, Rockford, IL 61107.

出版信息

Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2302064120. doi: 10.1073/pnas.2302064120. Epub 2023 Jul 5.

DOI:10.1073/pnas.2302064120
PMID:37406101
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10334734/
Abstract

Type II topoisomerases transiently cleave duplex DNA as part of a strand passage mechanism that helps control chromosomal organization and superstructure. Aberrant DNA cleavage can result in genomic instability, and how topoisomerase activity is controlled to prevent unwanted breaks is poorly understood. Using a genetic screen, we identified mutations in the beta isoform of human topoisomerase II (hTOP2β) that render the enzyme hypersensitive to the chemotherapeutic agent etoposide. Several of these variants were unexpectedly found to display hypercleavage behavior in vitro and to be capable of inducing cell lethality in a DNA repair-deficient background; surprisingly, a subset of these mutations were also observed in sequences from cancer genome databases. Using molecular dynamics simulations and computational network analyses, we found that many of the mutations obtained from the screen map to interfacial points between structurally coupled elements, and that dynamical modeling could be used to identify other damage-inducing alleles present in cancer genome databases. This work establishes that there is an innate link between DNA cleavage predisposition and sensitivity to topoisomerase II poisons, and that certain sequence variants of human type II topoisomerases found in cancer cells can act as DNA-damaging agents. Our findings underscore the potential for hTOP2β to function as a clastogen capable of generating DNA damage that may promote or support cellular transformation.

摘要

II 型拓扑异构酶作为链转移机制的一部分短暂地切割双链 DNA,该机制有助于控制染色体的组织和超结构。异常的 DNA 切割会导致基因组不稳定,而如何控制拓扑异构酶活性以防止不必要的断裂仍知之甚少。我们使用遗传筛选鉴定了人拓扑异构酶 II(hTOP2β)的β同工型中的突变,这些突变使该酶对化疗药物依托泊苷高度敏感。这些变体中的几个出乎意料地在体外显示出过度切割行为,并能够在 DNA 修复缺陷背景下诱导细胞致死;令人惊讶的是,这些突变中的一部分也在癌症基因组数据库中的序列中观察到。使用分子动力学模拟和计算网络分析,我们发现从筛选中获得的许多突变映射到结构偶联元件之间的界面点,并且动力学建模可用于识别癌症基因组数据库中存在的其他诱导损伤等位基因。这项工作确立了 DNA 切割倾向与拓扑异构酶 II 毒物敏感性之间存在内在联系,并且在癌细胞中发现的某些人类 II 型拓扑异构酶的序列变体可以作为 DNA 损伤剂。我们的发现强调了 hTOP2β 作为潜在的断裂剂的作用,它能够产生可能促进或支持细胞转化的 DNA 损伤。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/5a9495ad9006/pnas.2302064120fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/18b7ee4e2539/pnas.2302064120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/9527927a9895/pnas.2302064120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/0593831083b5/pnas.2302064120fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/3f9612db4c6e/pnas.2302064120fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/5a9495ad9006/pnas.2302064120fig05.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/18b7ee4e2539/pnas.2302064120fig01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/9527927a9895/pnas.2302064120fig02.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/0593831083b5/pnas.2302064120fig03.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/3f9612db4c6e/pnas.2302064120fig04.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0035/10334734/5a9495ad9006/pnas.2302064120fig05.jpg

相似文献

1
Naturally mutagenic sequence diversity in a human type II topoisomerase.人类 II 型拓扑异构酶中的自然突变序列多样性。
Proc Natl Acad Sci U S A. 2023 Jul 11;120(28):e2302064120. doi: 10.1073/pnas.2302064120. Epub 2023 Jul 5.
2
Etoposide-induced DNA damage is increased in p53 mutants: identification of ATR and other genes that influence effects of p53 mutations on Top2-induced cytotoxicity.依托泊苷诱导的 DNA 损伤在 p53 突变体中增加:鉴定影响 p53 突变对拓扑异构酶 2 诱导细胞毒性的 ATR 和其他基因。
Oncotarget. 2022 Feb 14;13:332-346. doi: 10.18632/oncotarget.28195. eCollection 2022.
3
Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.非同源末端连接途径在拓扑异构酶II介导的DNA损伤存活中的作用。
Mol Cancer Ther. 2006 Jun;5(6):1405-14. doi: 10.1158/1535-7163.MCT-05-0263.
4
Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.利用能量下坡-ATP 酶活性在 DNA 拓扑异构酶 II 中的遗传保护作用。
Nucleic Acids Res. 2024 Feb 9;52(3):1313-1324. doi: 10.1093/nar/gkad1157.
5
Etoposide, topoisomerase II and cancer.依托泊苷、拓扑异构酶II与癌症
Curr Med Chem Anticancer Agents. 2005 Jul;5(4):363-72. doi: 10.2174/1568011054222364.
6
Etoposide promotes DNA loop trapping and barrier formation by topoisomerase II.依托泊苷通过拓扑异构酶 II 促进 DNA 环捕获和障碍形成。
Nat Chem Biol. 2023 May;19(5):641-650. doi: 10.1038/s41589-022-01235-9. Epub 2023 Jan 30.
7
The sensitivity to DNA topoisomerase inhibitors in L5178Y lymphoma strains is not related to a primary defect of DNA topoisomerases.L5178Y淋巴瘤细胞系对DNA拓扑异构酶抑制剂的敏感性与DNA拓扑异构酶的原发性缺陷无关。
Carcinogenesis. 1993 Sep;14(9):1759-63. doi: 10.1093/carcin/14.9.1759.
8
1,2-Naphthoquinone as a Poison of Human Type II Topoisomerases.1,2-萘醌类化合物作为人类Ⅱ型拓扑异构酶的毒物。
Chem Res Toxicol. 2021 Apr 19;34(4):1082-1090. doi: 10.1021/acs.chemrestox.0c00492. Epub 2021 Mar 24.
9
Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.对双二氧哌嗪拓扑异构酶II催化抑制剂ICRF-187具有抗性的人小细胞肺癌NYH细胞,在α同工型的沃克A共有ATP结合结构域中表现出功能性R162Q突变。
Cancer Res. 1999 Jul 15;59(14):3442-50.
10
DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.DNA拓扑异构酶作为抗癌药物TAS-103的靶点:主要细胞靶点及DNA切割增强作用
Biochemistry. 1999 Nov 23;38(47):15573-9. doi: 10.1021/bi991791o.

引用本文的文献

1
Dynamic crosstalk between amino acid metabolism and cancer drug efficacy: From mechanisms to therapeutic opportunities.氨基酸代谢与癌症药物疗效之间的动态相互作用:从机制到治疗机遇
iScience. 2025 Apr 11;28(5):112405. doi: 10.1016/j.isci.2025.112405. eCollection 2025 May 16.
2
Yeast Tools for Studying Type II Topoisomerases in Budding Yeast.用于研究芽殖酵母中II型拓扑异构酶的酵母工具。
Methods Mol Biol. 2025;2928:123-150. doi: 10.1007/978-1-0716-4550-5_12.
3
Genome Instability Induced by Topoisomerase Misfunction.拓扑异构酶功能障碍导致的基因组不稳定性。

本文引用的文献

1
Recurrent mutations in topoisomerase IIα cause a previously undescribed mutator phenotype in human cancers.拓扑异构酶 IIα 的反复突变导致人类癌症中以前未描述的诱变表型。
Proc Natl Acad Sci U S A. 2022 Jan 25;119(4). doi: 10.1073/pnas.2114024119.
2
Trapped topoisomerase II initiates formation of de novo duplications via the nonhomologous end-joining pathway in yeast.拓扑异构酶 II 捕获物通过非同源末端连接途径在酵母中引发从头复制的形成。
Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26876-26884. doi: 10.1073/pnas.2008721117. Epub 2020 Oct 12.
3
Untangling trapped topoisomerases with tyrosyl-DNA phosphodiesterases.
Int J Mol Sci. 2024 Sep 24;25(19):10247. doi: 10.3390/ijms251910247.
4
Modeling allosteric mechanisms of eukaryotic type II topoisomerases.建模真核 II 型拓扑异构酶的变构机制。
Biophys J. 2024 Jun 18;123(12):1620-1634. doi: 10.1016/j.bpj.2024.05.004. Epub 2024 May 8.
5
Using energy to go downhill-a genoprotective role for ATPase activity in DNA topoisomerase II.利用能量下坡-ATP 酶活性在 DNA 拓扑异构酶 II 中的遗传保护作用。
Nucleic Acids Res. 2024 Feb 9;52(3):1313-1324. doi: 10.1093/nar/gkad1157.
解开与酪氨酰-DNA 磷酸二酯酶纠缠的拓扑异构酶。
DNA Repair (Amst). 2020 Oct;94:102900. doi: 10.1016/j.dnarep.2020.102900. Epub 2020 Jun 18.
4
Leveraging protein dynamics to identify cancer mutational hotspots using 3D structures.利用蛋白质动力学,通过 3D 结构识别癌症突变热点。
Proc Natl Acad Sci U S A. 2019 Sep 17;116(38):18962-18970. doi: 10.1073/pnas.1901156116. Epub 2019 Aug 28.
5
DNA Damage by an essential enzyme: A delicate balance act on the tightrope.一种必需酶对 DNA 的损伤:在钢丝绳上的微妙平衡行为。
DNA Repair (Amst). 2019 Oct;82:102639. doi: 10.1016/j.dnarep.2019.102639. Epub 2019 Jul 9.
6
DNA Topoisomerase Inhibitors: Trapping a DNA-Cleaving Machine in Motion.DNA 拓扑异构酶抑制剂:捕获运动中的 DNA 切割机器。
J Mol Biol. 2019 Aug 23;431(18):3427-3449. doi: 10.1016/j.jmb.2019.07.008. Epub 2019 Jul 10.
7
A complex suite of loci and elements in eukaryotic type II topoisomerases determine selective sensitivity to distinct poisoning agents.真核 II 型拓扑异构酶中复杂的基因座和元件决定了对不同毒性剂的选择性敏感性。
Nucleic Acids Res. 2019 Sep 5;47(15):8163-8179. doi: 10.1093/nar/gkz579.
8
Roles of eukaryotic topoisomerases in transcription, replication and genomic stability.真核生物拓扑异构酶在转录、复制和基因组稳定性中的作用。
Nat Rev Mol Cell Biol. 2016 Nov;17(11):703-721. doi: 10.1038/nrm.2016.111. Epub 2016 Sep 21.
9
Topoisomerase II and leukemia.拓扑异构酶 II 与白血病。
Ann N Y Acad Sci. 2014 Mar;1310(1):98-110. doi: 10.1111/nyas.12358. Epub 2014 Feb 3.
10
The role of topoisomerase II beta on breakage and proximity of RUNX1 to partner alleles RUNX1T1 and EVI1.拓扑异构酶 IIβ 在 RUNX1 与伙伴基因 RUNX1T1 和 EVI1 断裂和接近中的作用。
Genes Chromosomes Cancer. 2014 Feb;53(2):117-28. doi: 10.1002/gcc.22124. Epub 2013 Nov 5.